hVIVO (LON:HVO) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

hVIVO plc (LON:HVO)’s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 6.99 and traded as high as GBX 8.70. hVIVO shares last traded at GBX 8.40, with a volume of 1,180,797 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Peel Hunt restated an “add” rating and issued a GBX 10 price objective on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital Group reissued a “buy” rating and set a GBX 25 target price on shares of hVIVO in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of GBX 17.50.

hVIVO Price Performance

The company has a debt-to-equity ratio of 33.70, a quick ratio of 1.16 and a current ratio of 1.60. The stock’s fifty day moving average price is GBX 7.02 and its 200-day moving average price is GBX 7.28. The firm has a market cap of £57.04 million, a PE ratio of 10.78 and a beta of 1.60.

Insider Activity

In other news, insider Yamin Mo’ Khan purchased 3,310,405 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were acquired at an average price of GBX 6 per share, with a total value of £198,624.30. Also, insider Stephen Pinkerton purchased 520,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average price of GBX 6 per share, for a total transaction of £31,200. Corporate insiders own 5.24% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.